INSTRUCTIONS FOR USE: Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

SCOPE: Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).
Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

**Medicare Members**

This *Company* policy may be applied to Medicare Plan members only when directed by a separate *Medicare* policy. Note that investigational services are considered “not medically necessary” for Medicare members.

**COVERAGE CRITERIA**

**Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)**

I. Allogeneic hematopoietic stem cell transplantation (HSCT) may be considered medically necessary as a treatment for all of the following indications (A.-E.):

   A. Leukemia or leukemia in remission
   B. Inherited and acquired marrow disorders, including but not limited to the following:
      1. Aplastic anemia
      2. Diamond-Blackfan anemia
      3. Fanconi’s anemia
      4. Sickle cell anemia
      5. Beta thalassemia major
      6. Myelodysplastic syndromes (MDS)
      7. Paroxysmal nocturnal hemoglobinuria
      8. Pure red cell aplasia
      9. Amegakaryocytosis
      10. Congenital thrombocytopenia
   C. Autoimmune diseases and inborn errors in metabolism and congenital immune deficiencies including the following
      1. Severe combined immunodeficiency disease (SCID)
      2. X-linked adrenoleukodystrophy and adrenomyeloneuropathy
      3. Mucopolysaccharidoses
      4. Chronic granulomatous disease
      5. Krabbe disease
      6. NK cell deficiency syndromes
7. DiGeorge (22q11.2 deletion) syndrome
8. Wiskott-Aldrich syndrome
D. Myelofibrosis for intermediate and high-risk individuals
E. Relapsed or refractory lymphomas (e.g. angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma) in patients who are not candidates for autologous stem cell transplantation.

II. Allogeneic hematopoietic stem cell transplantation (HSCT) is considered investigational when criterion I is not met, including but not limited to the treatment of multiple myeloma.

Autologous Stem Cell Transplantation (AuSCT)

III. Autologous stem cell transplantation (AuSCT) may be considered medically necessary as a treatment for any of the following indications (A.-E.):

A. Acute leukemia in remission who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched;
B. Resistant non-Hodgkin’s lymphomas or those presenting with poor prognostic features following an initial response;
C. Recurrent or refractory neuroblastoma;
D. Advanced Hodgkin’s disease who have failed conventional therapy and have no HLA-matched donor.
E. High-risk or relapsed neuroblastomas

IV. Autologous stem cell transplantation (AuSCT) may be considered medically necessary as a treatment for Revised International Staging System (R-ISS) stage II or III patients (see Policy Guidelines) when both of the following criteria are met (A.-B.):

A. Patient has either newly diagnosed or responsive multiple myeloma, with any of the following (1.-3.):
   1. Patients with previously untreated disease,
   2. Patients with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), or
   3. Those in responsive relapse; and
B. Patient has a adequate cardiac, hepatic, pulmonary, and renal function (or function that is sufficiently supported by dialysis).

V. High dose melphalan (HDM) together with autologous stem cell transplantation (AuSCT) may be considered medically necessary for any age group with primary amyloid light chain (AL) amyloidosis who meet the following criteria (A-B):

A. Amyloid deposition in 2 or fewer organs; and
B. Cardiac left ventricular ejection fraction (EF) greater than 45%.

VI. Tandem transplant may be considered medically necessary when both of the following criteria are met (A.-B.)

A. Patient is a candidate for autologous stem cell transplantation (AuSCT); and
B. Treatment is for one of the following conditions (1.-3.):
   1. Testicular tumors, either as salvage therapy or for those with platinum-refractory disease
   2. High-risk neuroblastomas (see Policy Guidelines)
   3. Multiple Myeloma if either of the following are true (a.-b.):
      a. Patient did not achieve at least a Very Good Partial Rate (VGPR) (see Policy Guidelines) after a previous autologous stem cell transplantation; or
      b. Patient has high-risk features (e.g. plasma cell leukemia, extramedullary disease)

VII. Autologous stem cell transplantation (AuSCT) is considered not medically necessary when criteria III.-VI. are not met, or for the treatment of any of the following indications (A-E):

   A. Acute leukemia not in remission
   B. Chronic granulocytic leukemia
   C. Solid tumors (other than neuroblastoma)
   D. Non primary AL amyloidosis
   E. Sickle cell disease

POLICY CROSS REFERENCES

- Stem Cell Therapy for Orthopedic Applications, MP36

The full Company portfolio of current Medical Policies is available online and can be accessed here.

POLICY GUIDELINES

This policy may be primarily based on the following Center for Medicare and Medicaid Services (CMS) guidance resources:

- Centers for Medicare & Medicaid Services National Coverage Determination (NCD) for Stem Cell Transplantation (Formerly 110.8.1) (110.23).¹

Table 1: Revised International Staging System (R-ISS) Criteria for Multiple Myeloma²

<table>
<thead>
<tr>
<th>Stage</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>All of the following</td>
</tr>
<tr>
<td></td>
<td>• B2M &lt;3.5 mg/L</td>
</tr>
<tr>
<td></td>
<td>• Serum albumin ≥ 3.5 g/dL</td>
</tr>
<tr>
<td></td>
<td>• Normal LDH</td>
</tr>
</tbody>
</table>

¹
²
• No del(17p), t(4;14), or t(14;16) by FISH

<table>
<thead>
<tr>
<th>Stage II</th>
<th>Neither stage I nor stage III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B2M ≥ 5.5 mg/L and elevated LDH</td>
</tr>
<tr>
<td></td>
<td>-and/or- Del(17p), t(4;14), or t(14;16) by FISH</td>
</tr>
</tbody>
</table>

**Very Good Partial Response (VGPR)**

The NCCN defines VGPR as no measurable monoclonal protein on serum or urine electrophoresis, but positive immunofixation electrophoresis (IFE).³

**High Risk Neuroblastoma**

Patients most commonly at the highest risk for disease progression and mortality are generally those who are older than 18 months of age and have either disseminated disease or localized disease with unfavorable markers such as MYCN amplification regardless of age.⁴

**BACKGROUND**

**Myelodysplastic Syndromes (MDS)**

Myelodysplastic Syndromes (MDS) refers to a group of diverse blood disorders in which the bone marrow does not produce enough healthy, functioning blood cells. These disorders are varied with regard to clinical characteristics, cytologic and pathologic features, and cytogenetics. The abnormal production of blood cells in the bone marrow leads to low blood cell counts, referred to as cytopenias, which are a hallmark feature of MDS along with a dysplastic and hypercellular-appearing bone marrow

**Hematopoietic stem cells**

Hematopoietic stem cells are multi-potent stem cells that give rise to all the blood cell types; these stem cells form blood and immune cells. A hematopoietic stem cell is a cell isolated from blood or bone marrow that can renew itself, differentiate to a variety of specialized cells, can mobilize out of the bone marrow into circulating blood, and can undergo programmed cell death, called apoptosis – a process by which cells that are unneeded or detrimental will self-destruct.

**Stem cell transplantation**

Stem cell transplantation is a process in which stem cells are harvested from either a patient’s (autologous) or donor’s (allogeneic) bone marrow or peripheral blood for intravenous infusion.
Autologous stem cell transplantation (AuSCT)

Autologous stem cell transplantation (AuSCT) is a technique for restoring stem cells using the patient’s own previously stored cells. AuSCT must be used to effect hematopoietic reconstitution following severely myelotoxic doses of chemotherapy (HDCT) and/or radiotherapy used to treat various malignancies.

Allogeneic hematopoietic stem cell transplantation (HSCT)

Allogeneic hematopoietic stem cell transplantation (HSCT) is a procedure in which a portion of a healthy donor’s stem cell or bone marrow is obtained and prepared for intravenous infusion. Allogeneic HSCT may be used to restore function in recipients having an inherited or acquired deficiency or defect.

CLINICAL EVIDENCE AND LITERATURE REVIEW

CLINICAL PRACTICE GUIDELINES

American Society for Blood and Marrow Transplantation

In 2015, the American Society for Blood and Marrow Transplantation published guidelines on ‘Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation’. In the guidelines, they recommend allogeneic HCT for treating sickle cell anemia, categorizing the indication as a C for “standard of care, clinical evidence available. This category includes “indications for which large clinical trials and observational studies are not available. However, HCT has been shown to be an effective therapy with acceptable risk of morbidity and mortality in sufficiently large single- or multi-center cohort studies. HCT can be considered as a treatment option for individual patients after careful evaluation of risks and benefits. As more evidence becomes available, some indications may be reclassified as “Standard of Care”. Furthermore, aplastic anemia and Thalassemia were rated S or “standard of care”. The following conditions were also rated R for the allogenic HCT, “standard of care, rare indication”:

1. Fanconi’s anemia,
2. Dyskeratosis congenita,
3. Blackfan-Diamond anemia,
4. Congenital amegakaryocytic thrombocytopenia,
5. Severe combined immunodeficiency,
6. T cell immunodeficiency,
7. SCID variants,
8. Wiskott-Aldrich syndrome,
9. Hemophagocytic disorders,
10. Lymphoproliferative disorders,
11. Severe congenital neutropenia,
12. Chronic granulomatous disease,
13. And other autoimmune and immune dysregulation disorders.

These indications include “rare diseases for which clinical trials and observational studies with sufficient number of patients are not currently feasible because of their very low incidence. However, single or multi-center or registry studies in relatively small cohorts of patients have show HCT to be effective treatment with acceptable risks of morbidity and mortality.” HCT can be considered as a treatment options for these patients after careful evaluation of risks and benefits.

Autologous HCT for high risk or relapsed neuroblastoma was also rated as S, “standard of care”.

The guidelines recommend against autologous HCT for sickle cell disease, aplastic anemia, or Thalassemia, because the current evidence and current practice do not support the routine use of HCT. The guidelines state, “However, this recommendation does not preclude investigation of HCT as a potential treatment and transplantation may be pursued for these indications within the context of a clinical trial.”
The NCCN guidelines on T-Cell Lymphomas (Version 3.2022) recommend allogenic hematopoietic cell transplant as an option for “consolidation/additional therapy” in patients with relapsed/refractory peripheral T-cell lymphomas who experienced complete or partial response to clinical therapy or second-line therapy regiments.6

The NCCN guidelines on Myeloproliferative Neoplasms (Version 3.2022) recommend the following:

“Allogeneic HCT is included as an option for patients with INT-1-risk MF [intermediate risk 1 myelofibrosis]. Although the outcomes following allogeneic HCT are better for patients with low-risk or INT-1-risk MF, due to high transplanted-related morbidity and mortality, treatment decisions regarding allogeneic HCT should be individualized for patients with INT-1-risk MF. Allogeneic HCT should be considered for low-risk or INT-1-risk MF inpatients with either refractory, transfusion-dependent anemia; circulating blast cells >2% in peripheral blood; or adverse cytogenetics…. Evaluation for allogeneic HCT is recommended for all patients with INT-2-risk and high-risk MF.”7

The NCCN Guidelines on Myelodysplastic Syndromes (Version 3.2022) recommend the following:

“Therapeutic options for MDS [myelodysplastic syndrome] include supportive care, low-intensity therapy, high-intensity therapy including allogeneic HCT, and participation in a clinical trial.”8

The NCCN Guidelines on Multiple Myeloma (Version 3.2023) recommend the following:

“Patients presenting with active (symptomatic) myeloma are initially treated with primary therapy and primary therapy is followed by high-dose chemotherapy with autologous hematopoietic cell transplant (HCT) in transfer-eligible patients... Allogeneic stem cell transplant should preferentially be done in the context of a trial when possible.”3

“According to the NCCN Multiple Myeloma Panel, a tandem transplant with or without maintenance therapy can be considered for all patients who are candidates for HCT and is an option for patients who do not achieve at least a VGPR after the first autologous HCT and those with high-risk features.”3

BILLING GUIDELINES AND CODING

<table>
<thead>
<tr>
<th>CODES*</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0263T</td>
</tr>
<tr>
<td></td>
<td>Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0264T</td>
<td>Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest</td>
</tr>
<tr>
<td>0265T</td>
<td>Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy</td>
</tr>
<tr>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic</td>
</tr>
<tr>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous</td>
</tr>
<tr>
<td>38207</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td>38208</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor</td>
</tr>
<tr>
<td>38209</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor</td>
</tr>
<tr>
<td>38210</td>
<td>Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion</td>
</tr>
<tr>
<td>38211</td>
<td>Transplant preparation of hematopoietic progenitor cells; tumor cell depletion</td>
</tr>
<tr>
<td>38212</td>
<td>Transplant preparation of hematopoietic progenitor cells; red blood cell removal</td>
</tr>
<tr>
<td>38213</td>
<td>Transplant preparation of hematopoietic progenitor cells; platelet depletion</td>
</tr>
<tr>
<td>38214</td>
<td>Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion</td>
</tr>
<tr>
<td>38215</td>
<td>Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
<tr>
<td>38242</td>
<td>Allogeneic lymphocyte infusions</td>
</tr>
</tbody>
</table>

**Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.

- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.

- **See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.**

- **HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.**
REFERENCES


POLICY REVISION HISTORY

<table>
<thead>
<tr>
<th>DATE</th>
<th>REVISION SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2023</td>
<td>Converted to new policy template.</td>
</tr>
</tbody>
</table>